Amid global concerns over the rapid spread of the new variant of COVID-19, vaccine manufacturers say they are working to develop Omicron-specific vaccines.
Germany’s BioNTech and its partner Pfizer announced Monday that the development of an adapted vaccine is part of standard procedure to tackle new variants.
Explaining it's collecting relevant data right now, the company also added that a tailor-made vaccine could be ready in about 1-hundred days if necessary.
Moderna said a new vaccine to fight the Omicron strain could be ready by early next year if required.
It added more information on the current vaccine's efficacy to provide protection against the new mutation would be available in the coming weeks.
AstraZeneca also said it's examining the impact of the new variant on its vaccine and antibody cocktail, adding the company is conducting research to collect related data.
It adds that its vaccine platform developed jointly with Oxford University enables a quick response to new variants.
Meanwhile, the CEO of Pfizer has expressed confidence that the company's COVID-19 treatment pills are effective against the Omicron variant.
Speaking on CNBC Monday, he also said the company is committed to delivering 80 million courses of the drug for which Pfizer has requested emergency use authorization.
As global drugmakers rush to combat the newly identified variant, South Korea's Celltrion says it has accelerated development of a nebulized formulation of neutralizing antibody cocktail treatment.
It explained that it's conducting a global phase one clinical trial, and anticipates the results to be available by the end of this year.
The race comes on the heels of WHO's warning that the Omicron variant poses a “very high” global risk, recommending that governments improve their ability to tackle variants and speed up vaccinations.
Kim Hyo-sun, Arirang News.